机构:[1]Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000[2]Department of Hematology, Affiliated Hospital of Hebei University, Baoding, Hebei 071000, P.R. China河北大学附属医院
The SH2 domain-containing inositol 5'-phosphatase 1 (SHIP1) has been implicated as a suppressor of hematopoietic transformation as its activity can inhibit the PI3K/Akt signaling pathway. Reduced activity of SHIP1 has been observed in acute myeloid leukemia (AML). SHIP1 is a target of microRNA-155 (miR-155). Therefore, the aim of the present study was to investigate the role of miR-155/SHIP1 in the pathogenesis of AML. We examined the levels of SHIP1 protein and miR-155 in tissue samples of patients with AML and in AML cell lines. In addition, we investigated cell proliferation, apoptosis and expression of SHIP1/PI3K/AKT pathway molecules in the THP-1 and U937 cell lines after miR-155 inhibitor or mimics were transfected. We showed that the levels of SHIP1 protein were significantly decreased in tissue samples of patients with some subtypes of AML (M4 or M5) and in AML cell lines with concomitant overexpression of miR-155. In addition, we demonstrated that decreased expression of SHIP1 in the AML cell lines was a consequence of increased levels of miR-155 and can therefore be reversed in vitro through inhibition of miR-155, with subsequent inhibition of cell proliferation and promotion of cell apoptosis. In conclusion, expression of the SHIP1 protein is targeted by miR-155 in AML. miR-155 acts as an onco-miR, and the miR-155/SHIP1/PI3K/AKT signaling pathway could play an important role in the pathogenesis of AML.
基金:
Special Research Fund of the Ministry of Health of China [201202017]; Natural Science Foundation of Hebei Province [H2012206139]
第一作者机构:[1]Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000
通讯作者:
通讯机构:[1]Department of Hematology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei 050000[*1]Department of Hematology,The Second Hospital of Hebei Medical University, Shijiazhuang,Hebei 050000, P.R. China
推荐引用方式(GB/T 7714):
Xue Hua,Hua Luo-Ming,Guo Ming,et al.SHIP1 is targeted by miR-155 in acute myeloid leukemia[J].ONCOLOGY REPORTS.2014,32(5):2253-2259.doi:10.3892/or.2014.3435.
APA:
Xue, Hua,Hua, Luo-Ming,Guo, Ming&Luo, Jian-Min.(2014).SHIP1 is targeted by miR-155 in acute myeloid leukemia.ONCOLOGY REPORTS,32,(5)
MLA:
Xue, Hua,et al."SHIP1 is targeted by miR-155 in acute myeloid leukemia".ONCOLOGY REPORTS 32..5(2014):2253-2259